FinscoFinsco

Biomarin Pharmaceutical (US.BMRN)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.BMRN · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion90.5%→
ROE1.7%↓
Cash Conversion209.1%↑
D/E Ratio0.23↓
Gross Margin74.6%↓
US.BMRN (Biomarin Pharmaceutical) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion    90.5%    →
ROE                1.7%    ↓
Cash Conversion  209.1%    ↑
D/E Ratio          0.23    ↓
Gross Margin      74.6%    ↓
Key Metrics
US.BMRN (Biomarin Pharmaceutical) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 90.5% →
ROE 1.7% ↓
Cash Conversion 209.1% ↑
D/E Ratio 0.23 ↓
Gross Margin 74.6% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies